What intranasal 5-MeO-DMT feels like: interviews with 32 psychedelic-naive adults

The question

What do the subjective effects of a nasal spray form of 5-MeO-DMT actually feel like, and how do they unfold over time in people who have never used a psychedelic?

What they did

Thirty-two healthy adults with no previous psychedelic experience took part in a double-blind, randomized, placebo-controlled phase 1 trial of escalating doses of a proprietary intranasal 5-MeO-DMT formulation (BPL-003). Shortly after their dosing sessions, participants were interviewed using microphenomenology, a structured interview method designed to draw out fine-grained detail about how an experience unfolds moment to moment. The researchers analyzed the interview transcripts both qualitatively and quantitatively. This is the first published qualitative study of 5-MeO-DMT’s subjective effects.

What they found

The interviews pointed to a common time course: effects came on quickly, peaked at 8-15 minutes, and gradually returned to baseline over 45-60 minutes. The overall intensity of effects rose with higher doses, and the doses tested were described as generally well tolerated. Compared with published accounts of other psychedelics, 5-MeO-DMT stood out for its short duration, relatively few visual effects, and strong emotional and bodily experiences. Participants also reported content the authors considered potentially therapeutically relevant, such as emotional breakthroughs and personal insights.

The fine print

This was a small phase 1 safety study in 32 healthy volunteers, not people with a mental health condition, so it says nothing about whether the drug treats any illness. The findings come from self-reported interviews after dosing, which depend on memory and on how participants describe hard-to-articulate experiences. The abstract gives no specific doses, no numerical tolerability or adverse-event data, and no follow-up beyond the dosing sessions. This summary is based on the abstract alone.

What it means

This study offers a first detailed map of what a short-acting nasal 5-MeO-DMT experience is like, which can help researchers prepare participants and design future trials, but it does not test whether the drug helps any condition.

Evidence grade: Low. A small qualitative interview sub-study nested in a phase 1 trial, with healthy volunteers and no clinical outcomes measured.

This summary is based on the study’s published abstract.